Rapport Therapeutics, Inc.
RAPP
$10.04
-$0.4271-4.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 19.20% | 3.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.25% | 8.69% | |||
| Operating Income | -15.25% | -8.69% | |||
| Income Before Tax | -20.44% | -13.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.44% | -13.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.44% | -13.93% | |||
| EBIT | -15.25% | -8.69% | |||
| EBITDA | -15.49% | -8.59% | |||
| EPS Basic | -19.76% | -13.24% | |||
| Normalized Basic EPS | -19.74% | -13.23% | |||
| EPS Diluted | -19.76% | -13.24% | |||
| Normalized Diluted EPS | -19.74% | -13.23% | |||
| Average Basic Shares Outstanding | 0.56% | 0.61% | |||
| Average Diluted Shares Outstanding | 0.56% | 0.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||